Anti-β-Alzheimer Therapies That Cut Attacks Hailed As 'huge Deal'
Request For Sample Copy@
Global Anti-β-Alzheimer Therapies Market Taxonomy:
By Distribution Channel:
A breakthrough therapy is expected to provide immense growth for the Anti-β-Alzheimer therapies market
In July 2015, Biogen Pharmaceuticals announced results from a prespecified interim analysis of PRIME, which was the Phase 1b placebo-controlled study of aducanumab in patients with prodromal or mild Alzheimer’s disease (AD). Phase I clinical trials were conducted on 166, patients, which showed significant progress by lowering of Amyloid beta levels in the brain and slowdown in cognitive function as compared to the control group who received placebo. Phase III efficacy trial showed significant cognitive results in FDA based specific memory tests. On the other hand, in 2016, Eli Lilly and Company announced the development of Alzheimer drug solanezumab, which was in phase III clinical trial due to its slow progression of the Alzheimer disease and high cost.
In 2012, Pfizer Inc. and Johnson & Johnson, announced to discontinue the development of Alzheimer drug which was in intravenous (IV) form – bapineuzumab as drug failed to help patient with memory robbing condition in a second high profile clinical trial. Such failures, deter the expected growth of a market.
Increasing prevalence and incidence of Alzheimer disease is expected to favor the growth of Anti-β-Alzheimer therapies market
Increasing aging population along with its associated complications, such as dementia is the major driving factor for the growth of Anti-β-Alzheimer therapies market. For instance, according to Centers of Disease Control and Prevention (CDC), 2013, five million Americans were suffering from AD and the number is expected to rise up to 14 million by 2050. Moreover, according to World Health Organization (WHO), 2017, approximately 47 million people have dementia and nearly 10 million new cases are reported annually.
According to Australian Bureau of Statistics (ABS) in 2013, dementia was the second leading cause of death in Australia. According to Australian Institute of Health and Welfare (AIHW) estimates, the number of people with dementia is expected to reach around 400,000 by 2020, and around 900,000 by 2050. The National Health and Medical Research Council (NHMRC) is working in collaboration with the Australian Research Council (ARC) to priorities and fund new dementia research projects and translate research to improve prevention, diagnosis, treatment and care for dementia patients. Increasing prevalence and incidence of Alzheimer disease and its complication worldwide and rise in demand for therapy is expected to favor the growth of Anti-β-Alzheimer therapies market in near future.
Biogen Pharmaceuticals is a key player dominating the global Anti-β-Alzheimer therapies market.
Get More Details On this Report:
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Coherent Market Insights
1001 4th Ave,
Seattle, WA 98154
Visit our news Website: http://www.coherentchronicle.com
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Anti-β-Alzheimer Therapies That Cut Attacks Hailed As 'huge Deal' here
News-ID: 945334 • Views: 468
More Releases from Pharamceutical
Interventional Oncology Solutions Market Ablation Radiofrequency Ablation, Cryo …
Interventional oncology is a field of medical science, which includes treatment and diagnosis of cancer and other problems related to cancer using minimally invasive procedures. Interventional oncology uses various techniques such as Ultrasound, computed tomography, X-ray, and magnetic resonance imaging (MRI) to treat tumors located in various organs of the body. Interventional oncology procedures are usually used to treat metastatic or primary cancer. These procedures can be used to treat
Congestive Heart Failure Drugs Market, by Drug Type ACE Inhibitors, Angiotensin …
Major driver for growth of the congestive heart failure drugs market is the robust pipeline of drugs under development. For instance, furosemide injection solution (SCP-101) sponsored by Johns Hopkins University in collaboration with Scpharmaceuticals Inc. was in phase 2 clinical trials in 2015, this injection is indicated for treatment of heart failure. Furosemide and Azosemide sponsored by Hyogo College of Medicine has completed phase 4 clinical trials in 2016, these
New improved medication with lesser side effects will drive the insomnia therape …
Benzodiazepines (BZP) such as temazepam and diazepam are the commonly prescribed medication for insomnia. Though these medications are effective, prolonged use of these drugs may cause cognitive impairment, dependency and addiction. The launch of novel drugs such as Intermezzo (2014), tasimelteon (2014) have created a meteoric growth in G7 countries in the insomnia therapeutics and is expected market over the forecast period. Intermezzo (2014), are used in small doses and administered
Antiepileptic Drugs Market - Global Industry Insights,
Antiepileptic Drugs Market Regional Analysis North America and Europe are expected to witness significant growth in the market over the forecast period due to robust pipeline for epilepsy treatment and individual efforts by leading manufacturers. For instance, Pfizer, Inc. entered into partnership with Epilepsy Foundation to find solutions for generic forms of epilepsy and associated neurological disorders in 2014. Asia Pacific region is expected to show positive developments over the forecast
More Releases for Alzheimer
Alzheimer Disease Drugs Market Global Trends, Market Share, Industry Size, Growt …
Alzheimer’s disease is the most common cause of dementia among older people. It is a devastating condition for those afflicted as well as their family members and caregivers; the situation is only getting worse as the population ages. With the ageing global population, the number of patients suffering from Alzheimer’s disease is predicted to grow during the forecasting period. Alzheimer's treatment is a high risk, high reward market. Drugs currently
Anti-β-Alzheimer Therapies Market Analysis with Technological Advancement and G …
Alzheimer disease (AD) is a type of dementia that affects memory, thinking, language and behavior. Increasing age and high number of people suffering from Alzheimer's with age 65 and older are the major risk factors for progression of this disorder. It starts with mild symptoms and ends with severe brain damage in which individuals lose the ability to carry on a conversation and respond to their environment. According to Alzheimer
Alzheimer Diagnostic Tests Market - Medical Devices Pipeline Assessment, 2017 | …
"The Latest Research Report Alzheimer Diagnostic Tests - Medical Devices Pipeline Assessment, 2017 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" About Alzheimer Diagnostic Tests Market GlobalData's Medical Devices sector report, Alzheimer Diagnostic Tests - Medical Devices Pipeline Assessment, 2017" provides an overview of Alzheimer Diagnostic Tests currently in pipeline stage. The report provides comprehensive information on the pipeline products with comparative analysis of
US Alzheimer Drug Pipeline Analysis
In US, the Alzheimer's disease is the 6th leading cause of death overall and among those aged 65 and above, it is the 5th leading cause of death. While the deaths from major diseases, like heart disease have decreased, the death due to Alzheimer's have increased by more than 60% between 2000 and 2012. The total number of patients having Alzheimer’s disease was 5.4 million in 2012. Out of this,
Global Alzheimer Market Report: 2015 Edition | Now Available at Researchmoz.us
Researchmoz added Most up-to-date research on "Global Alzheimer Market Report: 2015 Edition" to its huge collection of research reports. Alzheimer’s disease is defined as an advanced neurological disorder that increasingly deprives patients of their memory and ability to carry out daily activities. As it grows in a human brain, individuals are likely to practice difficulties in linguistic, agility and insight along with negative changes in the character and performance such as
Personal GPS Tracker to Keep Care of Suffering Alzheimer Patients
A GPS tracker is appropriate for Letstrak who are worried about keeping track of their loved ones. Many Alzheimer’s patients can get lost accidentally as they have trouble remembering why they left home and where they are going. By using a tracker, Letstrak can keep track of elderly patients without needing to be by their side 24 hours per day. The device is easy to secure on the wrist and